Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex

• Status: Unknown status
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Rituximab, in the same doses as used in rheumatoid arthritis patients, will benefit pemphigus patients. It also tests immune function via the Cylex assay in pemphigus patients before and after treatment with RItuximab.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rabin Medical Center
• Collaborator: Leumit Health Services
• Treatments: Rituximab

Criteria

Inclusion Criteria:

1. Pemphigus patients with moderate-severe disease

Exclusion Criteria:

1. Pregnancy or lactation

2. Woman of reproductive age not using birth control measures.

3. Prior severe allergy or anaphylaxis with a human monoclonal antibody

4. Heart failure

5. Unstable angina or ischemic heart disease

6. Uncontrolled arrhythmia

7. HIV positive

8. Active hepatitis B infection or positive for hepatitis C virus (HCV) antibodies.

9. Severe dementia or a psychiatric illness

10. Active acute infection